A5072278925- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Bioactive Compounds and Antitumor Agents
- Bladder and Urothelial Cancer Treatments
- Nanomaterials for catalytic reactions
- Boron Compounds in Chemistry
- Pharmacological Effects and Toxicity Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- PI3K/AKT/mTOR signaling in cancer
- MXene and MAX Phase Materials
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Semiconductor materials and devices
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Head and Neck Cancer Studies
- Cancer-related gene regulation
- Histone Deacetylase Inhibitors Research
Texas Oncology
2013-2020
The US Oncology Network
2016-2019
McKesson (United States)
2014-2018
The University of Texas MD Anderson Cancer Center
2007-2012
Fort Worth Library
2012
Saginaw Valley State University
2007
Philadelphia University
2007
Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 NCT03085888) assessed the performance of targeted methylation analysis circulating cell-free DNA (cfDNA) to detect localize multiple types across all stages high specificity.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy safety of the combination were explored in patients metastatic renal cell carcinoma (mRCC).
6016 Background: Lenvatinib (LEN) is a multikinase inhibitor of vascular endothelial growth factor receptor 1−3, fibroblast 1−4, platelet-derived α, RET, and KIT. Pembrolizumab (PEM) an anti-PD-1 antibody approved for the second-line treatment recurrent or metastatic squamous cell carcinoma head neck (SCCHN) based on durable responses objective response rate (ORR) 16% (Bauml J et al, Clin Oncol 2017). We report initial results SCCHN cohort from phase 1b/2 trial LEN + PEM combination...
A Y-chromosome multiplex polymerase chain reaction (PCR) amplification kit, known as Y-PLEX 6, has been developed for use in human identification. The 6 kit enables simultaneous of six polymorphic short tandem repeat (STR) loci located on the non-recombinant region Y-chromosome. These are: DYS393, DYS19, DYS38911, DYS390, DYS391, and DYS385. Our studies show that little 0.2 ng template DNA can be used analysis. specificity enabled analysis male a male:female mixture at ratio 1:125. Among...
5034 Background: Perifosine, a synthetic alkylphospholipid, inhibits or modulates number of different signal transduction pathways (AKT, MAPK and JNK). In prior trial, 15 RCC patients (pts) were enrolled in randomized dose finding study, 9 evaluable for response 3 (33%) had partial (PR). Thus phase II trials begun pts who been treated with one VEGFr inhibitor (Group A) mTOR B). We report the results Group A (closed), B (enrollment open). Methods: To measure objective rate (RECIST) PFS to...
196 Background: Cancer stemness is thought to be associated with resistance chemotherapies. BBI608, a first-in-class cancer inhibitor that works through inhibiting the Stat3 pathway, has shown potent synergistic anti-tumor activity paclitaxel in vivo. In phase Ib dose escalation study patients advanced solid tumors, BBI608 plus weekly was well tolerated and RP2D of 480 mg BID determined. Methods: Patients heavily pretreated metastatic pancreatic adenocarcinoma were enrolled Ib/II extension...
To determine the clinical activity and safety of combination pemetrexed gemcitabine in advanced nonclear cell renal carcinoma (nccRCC).In this phase II study, patients received 500 mg/m intravenous infusion over 10 minutes on day 1 followed immediately by 1500 intravenously 30 1, with cycles repeated every 14 days. Planned enrollment was 40 patients. The primary endpoints were objective response rate progression-free survival (PFS). secondary overall survival.Between December 2005 2008, 16...
4077 Background: Napabucasin, a first-in-class cancer stemness inhibitor in clinical development, suppresses by targeting STAT3-driven gene transcription. Amcasertib targets multiple serine threonine kinases and inhibits Nanog other pathways. Preclinically, potent broad-spectrum anti-cancer activity was observed vitro vivo, alone combination with sorafenib. Methods: A phase Ib/II open-label, multi-center study adult patients advanced HCC who have not received prior systemic chemotherapy...
9093 Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that works through inhibiting the STAT3 pathway, and it has shown potent synergistic anti-tumor activity with paclitaxel in vivo. In phase Ib dose escalation study patients (pts) advanced solid tumors, BB608 plus weekly was well tolerated. Phase II accrual to disease-specific cohorts included advanced, heavily pre-treated metastatic non-small cell lung (NSCLC). Methods: Pts squamous or non-squamous...
5578 Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor targeting the STAT3 pathway that has shown potent synergistic anti-tumor activity with paclitaxel in vivo. In dose escalation study, BB608 plus weekly was well tolerated patients (pts) advanced solid tumors. RP2D expansion included accrual of pts platinum resistant ovarian (PROC). Methods: Pts epithelial ovarian, fallopian, or peritoneal who have progressed on prior taxane-based regimen and were...
9052 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of stem cells (Li et al PNAS 112 (6):1839, 2015). has shown potent synergistic preclinical anti-tumor activity with paclitaxel (PTX). In phase Ib dose escalation study in patients (pts) advanced solid tumors, napabucasin plus weekly PTX was well tolerated. A II expansion cohort opened for pts non-small cell lung (NSCLC). Methods:...
5548 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of stem cells (Li et al PNAS 112 (6):1839, 2015). has shown potent synergistic preclinical anti-tumor activity with paclitaxel (PTX). In phase Ib dose escalation study in patients (pts) advanced solid tumors, napabucasin plus weekly PTX was well tolerated. A II expansion cohort opened for platinum resistant ovarian cancer. Methods:...
TPS2598 Background: Treatment and survival of SCLC patients (pts) has remained mostly unchanged over past decades with high response rates to initial therapy (cisplatin/carboplatin + etoposide), but relapse is near universal median < 1 year in extensive disease. Delta-like protein 3 (DLL3) an inhibitory ligand the Notch receptor family identified as a novel target high-grade neuroendocrine tumors, highly expressed not normal tissue. Rovalpituzumab tesirine (Rova-T™) antibody-drug...
6032 Background: Amcasertib (BBI-503) is an oral first-in-class cancer stemness kinase inhibitor. By targeting multiple serine-threonine kinases, amcasertib inhibits Nanog and other pathways. A phase I clinical trial of showed safety signs anti-cancer activity in patients (pts) with advanced solid tumors during dose-escalation RP2D expansion, including pts head & neck cancer. Methods: Pts advanced, pre-treated cancers were enrolled. was administered orally, once or twice daily,...